Minnesota Oncology

Prostate Cancer News

Large Independent Validation Study Validates Oncotype DX Prostate Cancer Test (August 11, 2014)

Genomic Health, Inc. announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX® Genomic Prostate Score (GPS) predicts... Continue Reading

New Research Questions Early Prostate Cancer Treatment Options (July 28, 2014)

Researchers at The University of Texas MD Anderson Cancer Center recently published their latest findings on the role a diagnosing urologist plays in deciding whether older men with low-risk prostate cancer should receive treatment for their disease,... Continue Reading

Combination Hormone Therapy Appears Safe and Effective in Reducing Testosterone in Metastatic Prostate Cancer (June 18, 2014)

In a study presented at the 2014 American Society of Clinical Oncologists meeting, researchers reported that the use of two hormone blocking agents—Xtandi® (enzalutamide) and Zytiga® (abiraterone)—appeared safe and reduced testosterone levels in... Continue Reading

Xtandi Found to Delay Need for Chemotherapy in Metastatic Prostate Cancer Patients (June 16, 2014)

In results of a phase III trial reported at the 2014 American Society of Clinical Oncologists, treatment with Xtandi® (enzalutamide) was found to significantly delay the need for chemotherapy in metastatic prostate cancer patients previously treated... Continue Reading

Data Demonstrates Benefit of Utilizing Multiple Biological Pathways to Predict Tumor Behavior in Prostate and Renal Cancers (June 9, 2014)

REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today announced results of two studies demonstrating the ability of its Oncotype DX® test and a new 16-gene panel to predict disease aggressiveness and clinical... Continue Reading

Taxotere Added to Hormone Therapy Improves Overall Survival by 13 Months in Metastatic Prostate Cancer Patients (June 3, 2014)

In a study conducted by researchers at the Dana-Farber Cancer Institute, Taxotere® (docetaxel) administered with androgen-deprivation therapy to metastatic prostate cancer patients was found to extend overall survival by more than 13 months. The results... Continue Reading

New biopsy method shows prostate cancers considered ‘low risk’ may be anything but (May 22, 2014)

More and more men who have low-risk prostate cancers are forgoing treatment and opting for active surveillance, in which their tumors are closely monitored with PSA tests, digital rectal exams and ultrasounds at regular intervals. Nearly 400 men are now... Continue Reading

Radical Prostatectomy Offers Long-Term Benefit Over Watchful Waiting in Early Prostate Cancer (May 22, 2014)

Researchers in Sweden recently reported in The New England Journal of Medicine that radical prostatectomy continues to show long-term benefits over watchful waiting in early prostate cancer. Follow up studies in the Scandinavian Prostate Group Cancer... Continue Reading

Recent Studies Find Oncotype DX® Can Reliably Predict Risk of Aggressive Prostate Cancer (May 22, 2014)

Based on findings from three separate studies, it appears that the 17-gene Oncotype DX® Genomic Prostate Score (GPS) can help predict disease aggressiveness in prostate cancer at the time of diagnosis and therefore help physicians choose appropriate... Continue Reading

Xtandi Shows Significant Benefit in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer (April 21, 2014)

Xtandi® (enzalutamide) showed significant survival benefit in men with chemotherapy-naïve, metastatic, hormone-refractory prostate cancer, according to the results of a study presented at the 2014 European Association of Urology (EAU) Congress in Stockholm,... Continue Reading

Latest Prostate Cancer News By Stage


Early Stage I-II (A-B) Prostate Cancer

Large Independent Validation Study Validates Oncotype DX Prostate Cancer Test (August 11, 2014)

Genomic Health, Inc. announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX® Genomic Prostate Score (GPS) predicts... Continue Reading

New Research Questions Early Prostate Cancer Treatment Options (July 28, 2014)

Researchers at The University of Texas MD Anderson Cancer Center recently published their latest findings on the role a diagnosing urologist plays in deciding whether older men with low-risk prostate cancer should receive treatment for their disease,... Continue Reading

Data Demonstrates Benefit of Utilizing Multiple Biological Pathways to Predict Tumor Behavior in Prostate and Renal Cancers (June 9, 2014)

REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today announced results of two studies demonstrating the ability of its Oncotype DX® test and a new 16-gene panel to predict disease aggressiveness and clinical... Continue Reading

Radical Prostatectomy Offers Long-Term Benefit Over Watchful Waiting in Early Prostate Cancer (May 22, 2014)

Researchers in Sweden recently reported in The New England Journal of Medicine that radical prostatectomy continues to show long-term benefits over watchful waiting in early prostate cancer. Follow up studies in the Scandinavian Prostate Group Cancer... Continue Reading

Recent Studies Find Oncotype DX® Can Reliably Predict Risk of Aggressive Prostate Cancer (May 22, 2014)

Based on findings from three separate studies, it appears that the 17-gene Oncotype DX® Genomic Prostate Score (GPS) can help predict disease aggressiveness in prostate cancer at the time of diagnosis and therefore help physicians choose appropriate... Continue Reading

More Early Stage I-II (A-B) Prostate Cancer

Locally Advanced Stage III (C) Prostate Cancer

Combination Hormone Therapy Appears Safe and Effective in Reducing Testosterone in Metastatic Prostate Cancer (June 18, 2014)

In a study presented at the 2014 American Society of Clinical Oncologists meeting, researchers reported that the use of two hormone blocking agents—Xtandi® (enzalutamide) and Zytiga® (abiraterone)—appeared safe and reduced testosterone levels in... Continue Reading

High Incidence of Many Complications after Surgery or Radiation for Prostate Cancer (February 27, 2014)

Men who undergo surgery or radiation therapy for prostate cancer may face a variety of complications in addition to incontinence and erectile dysfunction—including high rates of hospitalization, urologic procedures, anal/rectal procedures, open surgeries,... Continue Reading

Metformin May Improve Survival in Diabetic Men with Prostate Cancer (September 4, 2013)

Diabetic men with prostate cancer lived significantly longer and were significantly less likely to die of prostate cancer when treated with metformin, an insulin-lowering drug, according to the results of a study published in Journal of Clinical Oncology. Prostate... Continue Reading

ASTRO and AUA Issue Joint Guideline for Radiation After Prostate Surgery (June 19, 2013)

The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) have issued a joint guideline regarding the use of radiation therapy after prostatectomy. It marks the first time the two medical organizations—most responsible... Continue Reading

Genomic Test May Help Guide Prostate Cancer Treatment (May 13, 2013)

A new genetic test—the Oncotype DX® Prostate Cancer Test—measures the aggressiveness of prostate cancer and may help scores of men choose between immediate treatment or active surveillance. The test was shown to strongly predict aggressiveness of... Continue Reading

More Locally Advanced Stage III (C) Prostate Cancer

Metastatic Stage IV (D) Prostate Cancer

Combination Hormone Therapy Appears Safe and Effective in Reducing Testosterone in Metastatic Prostate Cancer (June 18, 2014)

In a study presented at the 2014 American Society of Clinical Oncologists meeting, researchers reported that the use of two hormone blocking agents—Xtandi® (enzalutamide) and Zytiga® (abiraterone)—appeared safe and reduced testosterone levels in... Continue Reading

Xtandi Found to Delay Need for Chemotherapy in Metastatic Prostate Cancer Patients (June 16, 2014)

In results of a phase III trial reported at the 2014 American Society of Clinical Oncologists, treatment with Xtandi® (enzalutamide) was found to significantly delay the need for chemotherapy in metastatic prostate cancer patients previously treated... Continue Reading

Taxotere Added to Hormone Therapy Improves Overall Survival by 13 Months in Metastatic Prostate Cancer Patients (June 3, 2014)

In a study conducted by researchers at the Dana-Farber Cancer Institute, Taxotere® (docetaxel) administered with androgen-deprivation therapy to metastatic prostate cancer patients was found to extend overall survival by more than 13 months. The results... Continue Reading

Xtandi Shows Significant Benefit in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer (April 21, 2014)

Xtandi® (enzalutamide) showed significant survival benefit in men with chemotherapy-naïve, metastatic, hormone-refractory prostate cancer, according to the results of a study presented at the 2014 European Association of Urology (EAU) Congress in Stockholm,... Continue Reading

High Incidence of Many Complications after Surgery or Radiation for Prostate Cancer (February 27, 2014)

Men who undergo surgery or radiation therapy for prostate cancer may face a variety of complications in addition to incontinence and erectile dysfunction—including high rates of hospitalization, urologic procedures, anal/rectal procedures, open surgeries,... Continue Reading

More Metastatic Stage IV (D) Prostate Cancer

Refactory/Recurrent Prostate Cancer

Combination Hormone Therapy Appears Safe and Effective in Reducing Testosterone in Metastatic Prostate Cancer (June 18, 2014)

In a study presented at the 2014 American Society of Clinical Oncologists meeting, researchers reported that the use of two hormone blocking agents—Xtandi® (enzalutamide) and Zytiga® (abiraterone)—appeared safe and reduced testosterone levels in... Continue Reading

Taxotere Added to Hormone Therapy Improves Overall Survival by 13 Months in Metastatic Prostate Cancer Patients (June 3, 2014)

In a study conducted by researchers at the Dana-Farber Cancer Institute, Taxotere® (docetaxel) administered with androgen-deprivation therapy to metastatic prostate cancer patients was found to extend overall survival by more than 13 months. The results... Continue Reading

Xtandi Shows Significant Benefit in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer (April 21, 2014)

Xtandi® (enzalutamide) showed significant survival benefit in men with chemotherapy-naïve, metastatic, hormone-refractory prostate cancer, according to the results of a study presented at the 2014 European Association of Urology (EAU) Congress in Stockholm,... Continue Reading

High Incidence of Many Complications after Surgery or Radiation for Prostate Cancer (February 27, 2014)

Men who undergo surgery or radiation therapy for prostate cancer may face a variety of complications in addition to incontinence and erectile dysfunction—including high rates of hospitalization, urologic procedures, anal/rectal procedures, open surgeries,... Continue Reading

Xtandi Improves Survival in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer (February 19, 2014)

Xtandi® (enzalutamide) improved survival and reduced the risk of radiographic progression in men with chemotherapy-naïve, metastatic, hormone-refractory prostate cancer, according to the results of a study presented at the 2014 Genitourinary Cancers... Continue Reading

More Refactory/Recurrent Prostate Cancer

Screening/Prevention Prostate Cancer

Omega-3 Fatty Acids Linked to Increased Risk of Prostate Cancer (August 23, 2013)

Omega-3 fatty acids may be linked to an increased risk of prostate cancer, according to the results of a study published in the Journal of the National Cancer Institute. Other than skin cancer, prostate cancer is the most commonly diagnosed cancer in... Continue Reading

Prostate Cancer Screening Can Take a Toll on Quality of Life (December 19, 2012)

Screening for prostate cancer carries some risks and can affect quality of life. Considering these risks is important when making the decision about whether to be screened. The results of a study that assessed both the potential benefits of screening... Continue Reading

Aspirin and Cancer Risk and Mortality (September 17, 2012)

Aspirin and cancer risk is in the news again—and the link is still unclear. Two studies published early online in the Journal of Clinical Oncology evaluated the relationship between aspirin and cancer risk—one indicated that aspirin does not appear... Continue Reading

New Screening Method May Help Diagnose Undetectable Prostate Cancer (August 16, 2012)

Men with persistently increased or fluctuating prostate specific antigen (PSA) levels and a negative prostate biopsy may benefit from a new prostate cancer screening method that uses the combination of a novel drug therapy plus changes in PSA levels over... Continue Reading

PSA Testing May Be Appropriate for Some Men (July 25, 2012)

The American Society of Clinical Oncology (ASCO) has released a Provisional Clinical Opinion (PCO) suggesting that that men with a longer life expectancy—those with at least 10 more years to live—discuss with their physician the potential risks and... Continue Reading

More Screening/Prevention Prostate Cancer